Predicting the Level of Tumor-Infiltrating Lymphocytes in Patients With Breast Cancer: Usefulness of Mammographic Radiomics Features

Hongwei Yu¹, Xianqi Meng², Huang Chen³, Jian Liu⁴, Wenwen Gao¹,⁵, Lei Du¹,⁶, Yue Chen¹,⁵, Yige Wang¹,⁶, Xiuxiu Liu¹,⁵, Bing Liu¹,⁶, Jingfan Fan²* and Guolin Ma¹*

¹ Department of Radiology, China-Japan Friendship Hospital, Beijing, China, ² Beijing Engineering Research Center of Mixed Reality and Advanced Display, School of Optics and Photonics, Beijing Institute of Technology, Beijing, China, ³ Department of Pathology, China-Japan Friendship Hospital, Beijing, China, ⁴ Department of Ultrasound medicine, China-Japan Friendship Hospital, Beijing, China, ⁵ Peking University China-Japan Friendship School of Clinical Medicine, Beijing, China, ⁶ Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Objectives: This study aimed to investigate whether radiomics classifiers from mammography can help predict tumor-infiltrating lymphocyte (TIL) levels in breast cancer.

Methods: Data from 121 consecutive patients with pathologically-proven breast cancer who underwent preoperative mammography from February 2018 to May 2019 were retrospectively analyzed. Patients were randomly divided into a training dataset (n = 85) and a validation dataset (n = 36). A total of 612 quantitative radiomics features were extracted from mammograms using the Pyradiomics software. Radiomics feature selection and radiomics classifier were generated through recursive feature elimination and logistic regression analysis model. The relationship between radiomics features and TIL levels in breast cancer patients was explored. The predictive capacity of the radiomics classifiers for the TIL levels was investigated through receiver operating characteristic curves in the training and validation sets. A radiomics score (Rad score) was generated using a logistic regression analysis method to compute the training and validation datasets, and combining the Mann–Whitney U test to evaluate the level of TILs in the low and high groups.

Results: Among the 121 patients, 32 (26.44%) exhibited high TIL levels, and 89 (73.56%) showed low TIL levels. The ER negativity (p = 0.01) and the Ki-67 negative threshold level (p = 0.03) in the low TIL group was higher than that in the high TIL group. Through the radiomics feature selection, six top-class features [Wavelet GLDM low gray-level emphasis (mediolateral oblique, MLO), GLRLM short-run low gray-level emphasis (craniocaudal, CC), LBP2D GLRLM short-run high gray-level emphasis (CC), LBP2D GLDM dependence entropy (MLO), wavelet interquartile range (MLO), and LBP2D median (MLO)] were selected to constitute the radiomics classifiers. The radiomics classifier had an excellent predictive performance for TIL levels both in the training and validation sets [area under the curve (AUC): 0.83, 95% confidence interval (CI), 0.738–0.917, with...
INTRODUCTION

Breast cancer is the most common malignant tumor among women globally, with a high mortality rate, making early correct diagnosis and effective treatment essential. In recent years, immunotherapy and immune checkpoint blockade (ICB) for the treatment of breast cancer patients have raised concerns in clinical practice (1, 2). However, only a portion of patients respond to treatment of breast cancer patients have raised concerns in clinical practice (1, 2). However, only a portion of patients respond to current immunotherapy, and predictive biomarkers are necessary for patients who are suitable for immunotherapy (3).

Tumor-infiltrating lymphocytes (TILs) is a promising biomarker, it is now known that the success of ICB-based immunotherapy requires pre-existing anti-tumor immunity (4), which can reflect an individual’s immune tumor response and has strong prognostic and predictive significance (5–7). Increased TIL levels positively correlate with pathological complete response (pCR) and improved patient survival rates, especially in triple-negative breast cancer (TNBC) and human epidermal growth factor receptor 2 (HER 2)-positive breast cancer subtypes. Although the International Immunoo-Oncology Biomarker Working Group on Breast Cancer has issued the latest TIL assessment guidelines, the process is still laborious and subjective, with variability between and within raters (8). Therefore, a more objective and reliable method to evaluate TILs in breast tumor is essential.

Radiomics is a recently emerging technique in computational medical imaging and involves extraction and analyses of a large number of quantitative imaging features, such as volume, size, shape, and intensity from medical images. It is different from traditional methods because it converts medical images into mineable high-dimensional data (9, 10). Radiomics can help support patient diagnosis, prognosis, treatment, and prediction in clinical practice (11–13). Magnetic resonance imaging (MRI) plays an important role in the diagnosis of breast cancer, and a few recent studies reported its correlation with the clinical decision among breast cancer patients (14, 15). In addition, several studies have shown that quantitative imaging features from MRI can predict TIL levels and molecular subtypes in patients with breast cancer (16, 17). On the other hand, mammography is a simple, convenient, and low-cost examination without contrast agent injection, compared with MRI. It is widely used in breast cancer screening and diagnosis. Recently, a study demonstrated that quantitative radiomics features derived from mammography can distinguish high and low TILs in patients with TNBC (18). Another study showed that radiomics with mammography can predict breast cancer molecular subtypes (19). However, there are no studies that predict the relationship between TIL levels and breast cancer through mammography. Preoperative evaluation of TILs is a significant biomarker of prognosis and therapeutic response. Therefore, the aim of this study was to evaluate the usefulness of a radiomics model from mammography data in predicting TIL levels in breast cancer patients.

MATERIALS AND METHODS

Patients and Imaging Dataset

This retrospective study was approved by the Institutional Ethics Review Committee of the China–Japan Friendship Hospital, and the requirement for informed consent was waived for all patients. Between February 2018 and May 2019, 121 consecutive patients with breast cancer were enrolled in this study. The inclusion criteria were as follows: (1) unilateral mass type breast cancer was recruited; (2) preoperative bilateral mammography must be performed; (3) having complete clinical data; (4) having complete pathological data, including postoperative immunohistochemical results. All patients received preoperative mammograms through a digital technique using Lorad Selenia (Hologic Gen-Probe, San Diego, USA). The quantization was set to 14-bit for the full-field digital mammographic images with pixel sizes of 70 μm × 70 μm. Images of the craniocaudal (CC) view and the mediolateral oblique (MLO) view were obtained from mammograms of each patient. A total of 121 single masses were analyzed. 121 patients were randomly divided into the training dataset (n = 85) and the validation dataset (n =36) using statistical software.

Tumor Segmentation and Radiomics Feature Extraction

A radiologist with more than ten years of work experience manually outlined tumor edges in the image. The three-dimensional segmentation of tumor regions of interest (ROIs) was performed using the ITK-SNAP software (version 3.8, Philly, PA, USA), in which the radiological characteristic of the lesion area was extracted. A total of 612 first order shape texture wavelet lbp2d features were extracted using the Pyradiomics software (version 2.2.0, Boston, MA, USA). These radiomics features included texture, morphologic, and statistical features of gray values. Shape, perimeter, area, and size represented the morphological characteristics. Correlation, entropy, contrast,
inertia, and homogeneity were the texture features extracted. Finally, the statistical features of gray values involved kurtosis, variance, and gray average.

**Radiomics Feature Selection and Classifier Construction**

For the purpose of constructing a predictive model, a one-way analysis of variance (ANOVA) was applied to filter out features with a variance of 0, and then the rest of the radiomics features were retained to select the most relevant features using recursive feature elimination (RFE). According to the Mann–Whitney U test, the top-class features were screened out to build the final logistic regression classifier, which was used to perform radiomics feature selection in the training dataset. Classification performance was evaluated using the area under the receiver operating characteristic curve (AUC). Finally, a radiomics score (Rad score) was developed using the logistic regression model and was used to calculate for the training and validation datasets.

**Evaluation of Tumor-Infiltrating Lymphocytes**

After hematoxylin and eosin (H&E) staining, the tumor tissue section was evaluated by a pathologist who had 20 years of professional experience in breast tumor diagnosis. The number of TILs was confirmed by the same pathologist. In order to facilitate the evaluation of variables, we divided the tumor samples into two groups: (1) the low TIL level group was defined as having a TIL density of <50%, and (2) the high TIL level group was defined as having a TIL density >50%. The evaluation criteria followed the latest TIL assessment guidelines issued by the International Immuno-Oncology Biomarker Working Group on Breast Cancer (8).

**Statistical Analysis**

All statistical tests were performed using SPSS software (SPSS, version 25, Chicago, IL, USA). A p value <0.05 was considered statistically significant. To evaluate the disparity among the patients’ clinicopathologic characteristics, the chi-square test was used for categorical variables. ANOVA was used to filter out features with a variance of 0. The top-radiological features were correlated with the logistic regression classification using the Mann–Whitney U test. To assess the difference between the predictable competence of the high and low TIL levels based on the training and validation datasets, ROC curves were developed. A Rad score was generated using a logistic regression model to calculate the training dataset and validation dataset.

**RESULTS**

**Patients’ Characteristics**

The basic characteristics of the patients are shown in Table 1. Among the 121 patients, 32 (26.44%) exhibited high TIL levels, whereas 89 (73.56%) showed low TIL levels. The mean ages and menopausal status of patients in the high and low TIL groups were not statistically significant (p = 0.87, p = 0.38), respectively.

| Variables | High TILs level (>50%) | Low TILs level (<50%) | p-value |
|-----------|------------------------|------------------------|---------|
| Age, years | 50.4 ± 8.9 | 50.7 ± 11.5 | 0.87 |
| Menopausal status | | | 0.38 |
| Premenopausal | 12(37.5%) | 26(29.2%) | |
| Postmenopausal | 20(62.5%) | 63(70.8%) | |
| Histologic grade | | | | |
| Grade 1 | 5(15.6%) | 10(11.2%) | 0.81 |
| Grade 2 | 16(50.0%) | 47(52.8%) | |
| Grade 3 | 11(34.4%) | 32(36.0%) | |
| Pathologic type | | | | |
| IDC | 22(68.8%) | 74(83.1%) | 0.22 |
| TLC | 6(18.8%) | 7(7.9%) | |
| Other | 4(12.5%) | 18(20.2%) | |
| ER | | | 0.01 |
| Positive | 7(21.9%) | 50(56.2%) | |
| Negative | 25(78.1%) | 38(43.8%) | |
| PR | | | 0.67 |
| Positive | 21(65.6%) | 62(69.7%) | |
| Negative | 11(34.4%) | 27(30.3%) | |
| HER2 | | | 0.17 |
| Positive | 9(28.1%) | 15(16.9%) | |
| Negative | 23(71.9%) | 74(83.1%) | |
| Molecular subtypes | | | 0.67 |
| Luminal A | 10(31.3%) | 36(39.3%) | |
| Luminal B | 12(37.5%) | 26(29.2%) | |
| HER2-enriched | 5(15.6%) | 18(20.2%) | |
| Triple negative | 5(15.6%) | 10(11.2%) | |
| Ki-67 | | | 0.03 |
| ≥14% | 5(15.6%) | 40(44.9%) | |
| <14% | 27(84.4%) | 49(55.1%) | |

ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TILs, tumor-infiltrating lymphocytes.

The ER negativity and the Ki-67 negative threshold level in the low TIL group were higher than that in the high TIL group, and the difference between the two groups was statistically significant (p = 0.01 and p = 0.03, respectively). The patients’ characteristics in the training and validation datasets of this study are listed in Table 2. In terms of clinicopathological aspects, there was no statistical significance between the validation and training datasets.

**Radiomics Feature Selection and Classifier Construction**

The study flowchart is presented in Figure 1. A diagram of the breast tumor segment is shown in Figure 2. In total, 612 radiomics features that represent quantitative images were extracted from the CC and MLO of mammograms. Through ANOVA, all the features with a variance of 0 were eliminated, and 517 radiomics features remained after the analysis. Subsequently, ten features were selected for further evaluation through RFE, and then the six top-class features with p-values <0.05 were selected using the Mann–Whitney U test in the training set (Table 3). Figure 3 shows that the correlation between the top six features, including wavelet GLDM low gray level emphasis (MLO) (p = 0.018), GLRLM short run low gray level emphasis (CC) (p = 0.005), LBPD2 GLRLM short run high gray level emphasis (CC) (p = 0.014), LBPD2 GLDM dependence entropy (MLO) (p = 0.008), wavelet interquartile range (MLO) (p = 0.007), and LBPD2 median (MLO) (p = 0.004) and the training and validation datasets.
TABLE 2 | Characteristics of patients in the training set and validation sets.

| Characteristics          | Training set (n = 85) | Validation set (n = 36) | p-value |
|--------------------------|-----------------------|-------------------------|---------|
| Age, years               | 50.6 ± 10.5           | 52.3 ± 10.5             | 0.19    |
| Menopausal status        |                       |                         | 0.79    |
| premenopausal            | 24(28.2%)             | 11(30.6%)               |         |
| postmenopausal           | 61(71.8%)             | 25(69.4%)               |         |
| Histologic grade         |                       |                         | 0.95    |
| Grade 1                  | 20(23.5%)             | 8(22.2%)                |         |
| Grade 2                  | 40(47.1%)             | 18(50.0%)               |         |
| Grade 3                  | 25(29.4%)             | 10(27.8%)               |         |
| Pathologic type          |                       |                         | 0.42    |
| IDC                      | 72(84.7%)             | 30(83.3%)               |         |
| TLC                      | 10(11.8%)             | 6(16.7%)                |         |
| Other                    | 3(3.5%)               | 0(0%)                   |         |
| ER                       |                       |                         | 0.21    |
| Positive                 | 68(80.0%)             | 25(69.4%)               |         |
| Negative                 | 17(20.0%)             | 11(30.6%)               |         |
| PR                       |                       |                         | 0.28    |
| Positive                 | 56(65.9%)             | 20(55.6%)               |         |
| Negative                 | 29(34.1%)             | 16(44.4%)               |         |
| HER2                     |                       |                         | 0.72    |
| Positive                 | 19(22.4%)             | 7(19.4%)                |         |
| Negative                 | 66(77.6%)             | 29(80.6%)               |         |
| Molecular subtypes       |                       |                         | 0.81    |
| Luminal A                | 28(32.9%)             | 11(30.6%)               |         |
| Luminal B                | 37(43.5%)             | 14(38.9%)               |         |
| HER2-enriched            | 11(12.9%)             | 5(13.9%)                |         |
| Triple negative          | 9(10.8%)              | 6(16.7%)                |         |
| Ki-67                    |                       |                         | 0.93    |
| ≥14%                     | 55(64.7%)             | 23(63.9%)               |         |
| <14%                     | 30(35.3%)             | 13(36.1%)               |         |

ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.

0.017). Finally, the top six features were used to build radiomics classifiers based on logistic regression to predict the TIL level. A Rad score for the training and validation datasets was calculated.

Performance and Validation of the Radiomics Classifiers

The optimal cut-off value produced through the ROC curve analysis was 0.408. In both the training and validation sets, the radiomics classifier had an excellent performance for classifying the TIL levels. The AUC value was 0.83 (95% confidence interval [CI], 0.738–0.917) in the training dataset and had positive predictive value of 0.913. For the validation set, the classifier had an AUC value of 0.79 (95% CI, 0.615–0.964) and a positive predictive value of 0.889 (Table 4, Figure 4). The Rad scores for the training and validation sets with respect to the high and low TIL levels are described in Figure 5. The predictive performances as determined by Box-plot are presented as statistically different, with p <0.05 (training set p = 0.018, validation set p = 0.031).

DISCUSSION

For TNBC and HER 2-positive breast cancer patients, the TIL levels have a valuable prognostic and predictive ability (20). Many studies have shown that high TIL level is a significant predictor of prognosis and increased pCR rates after chemotherapy (21, 22). Furthermore, the combined application of TIL and clinicopathological criteria can be used to detect and identify early breast cancer patients with better prognosis and avoid unnecessary immunotherapy. Therefore, TILs could serve as useful predictive biomarkers to select patients who could potentially benefit from immunotherapy (1). However, because of the non-uniformity of TIL concentrations in the tumor, the outcome acquired through biopsy may not reflect the whole tumor tissue; the gold standard for evaluating TILs through pathologists’ visual assessment of H&E-stained tumor sections could also be limited mainly by observer diversity. On the other hand, medical imaging plays an irreplaceable role in tumor diagnosis, treatment, and treatment monitoring and is the most useful tool for oncology. Unlike biopsy, imaging is usually widely used in clinical practice because it can be used non-invasively to assess the characteristics of human tissues. Radiomics can extract information-rich imaging functions with high throughput, which is different from traditional subjective imaging and can quantify imaging information that the human eye cannot detect.

Previously, abundant evidence has reported on the relationship between TILs and MRI features. Wu et al. (23) showed that the density of TILs in tumors is closely related to the MRI enhancement form. Fogante et al. (24). used a slightly smaller ROI to assess the relationship between the ADC value and TIL level. Denkert et al. (25) showed that a higher density of TILs is correlated with improved efficacy of neoadjuvant chemotherapy in breast cancer patients, especially when the survival rates of TNBC and HER 2-positive patients are prolonged. However, MRI and mammography have different imaging characteristics, and no research has explored mammographic images in evaluating the status of TILs. Thus, analyzing the characteristics of breast cancer based on the morphology, density, and anatomical features of the mammogram is of great significance for the evaluation of TIL levels. A radiomics method to predict the tumor TIL levels among breast cancer patients was performed in this study. A total of six radiomics features were selected [Wavelet GLDM low gray level emphasis (MLO), GLRLM short-run low gray-level emphasis (CC), LBP2D GLRLM short-run high gray-level emphasis (CC), LBP2D GLDM dependence entropy (MLO), wavelet interquartile range (MLO), and LBP2D median (MLO)]. Wavelet GLDM low gray level emphasis represents the magnitude of a low gray value distribution. The higher the value, the greater the density of the low gray level in the image. GLRLM short run low gray level emphasis measures the joint distribution of shorter run lengths with lower gray level values. The LBP2D GLRLM short run high gray level emphasis measures the joint distribution of shorter run lengths with higher gray level values. LBP2D GLDM dependence entropy means the randomness of GLDM, and a higher dependence entropy implies a more complex texture. The wavelet interquartile range represents P25 and P75 are the 25th and 75th percentiles of the image array, respectively. The LBP2D median refers to the median gray level intensity within the ROI (26, 27).
FIGURE 1 | The workflow for feature engineering of mammographic radiomics, which included four main steps. Image acquisition and tumor segmentation; radiomics feature extraction and screening; predictive model building; model validation application.
In mathematics, the GLDM and GLRLM characteristics have different functions and definitions; thus, it has a very good advantage in measuring the heterogeneity of tumor texture features. These texture features based on GLDM and GLRLM are considered adjacent pixels, so it is very suitable for quantization of tumor texture and heterogeneity (28).
Many previous studies have underlined the importance of entropy (29, 30), but one study suspects that entropy is not suitable for the construction of elastic net regression because of the disadvantage of multicollinearity (31). We used the texture features that could interact with each other by combining traditional statistics to build the logical regression classifier. To filter out the coarse feature with redundant, noisy, and irrelevant dimensions, a relatively small subset of the radiomics characteristics was selected. The number of top-class features selected in the prediction model depends on the purpose and the problem to be solved in the process of constructing the classifier (32). In order to improve the accuracy of the predictive model, we combined the Mann–Whitney U test and logical regression classifier to select informative elements. Our results show that a predictive model and the correlation with TIL levels showed excellent discriminative ability among the low and high TIL.

**TABLE 4 |** The predictive performance of radiomics classifier in training and validation sets.

| Datasets   | Cutoff | AUC (95% CI)   | SEN  | SPE  | Accuracy | PPV  | NPV  |
|------------|--------|----------------|------|------|----------|------|------|
| Training   | 0.408  | 0.828(0.738, 0.918) | 0.913 | 0.629 | 0.706    | 0.477 | 0.951 |
| Validation | 0.408  | 0.790(0.616, 0.965) | 0.889 | 0.556 | 0.639    | 0.400 | 0.938 |

AUC, area under curve; 95% CI, 95% confidence interval; SEN, sensitivity; SPE, specificity; PPV, positive predictive value; NPV, negative predictive value.

**FIGURE 4 |** Receiver operating characteristic curves for predicting the TIL levels in the training datasets (A) and validation (B) datasets.

**FIGURE 5 |** Box plot shows Rad score distributions between the training (A) and validation (B) groups.
groups, with AUCs of 0.83 and 0.79 in the training and validation groups, respectively. Despite the limited number of tumor samples in the training and validation sets, the Rad score was able to identify the difference in TIL levels between these datasets. In our study, we observed that the high TIL levels had p-values that were less than that of the low TIL levels, according to the Mann–Whitney U test. The difference was also statistically significant.

Our study has two advantages. First, to the best of our knowledge, this is the first study wherein machine learning has been used to evaluate TIL levels among breast cancer patients. Our study demonstrated that radiomics from qualitative mammographic image characteristics can be used to predict TIL levels. Second, we used standardized texture values to build a logical regression classifier because all texture features had diverse ranges, which could increase the accuracy of predictive modeling.

However, our study also has some limitations. First, this study had a small sample size and was a single-centered retrospective study. Further studies involving multiple centers and a large number of patients are necessary. Second, our radiomics classifier was calculated using ROI drawn only on the single largest slice in the mammographic image, which may increase concerns regarding selection bias. Third, we did not perform an external validation to confirm the effectiveness of our findings, which may lead to differences. In the future, a larger subset of the dataset is needed for validation. Finally, we could not contrast the manifestation of mammograms and DC-EMR images in this study. However, mammography remains the most common method for breast cancer screening and diagnosis. This study aimed to investigate the predictive capacity between radiological features of mammograms and TIL levels in breast cancer patients. If radiomics predictive modeling from mammograms has excellent performance in evaluating TIL levels, more valuable information will be provided to radiologists and clinicians, which can help radiologists and clinicians to make better clinical decisions for breast cancer patients.

In conclusion, a radiomics predictive model from digital mammogram images was found to be a useful method for discriminating low and high TIL levels in patients with breast cancer. Such a quantitative radiomics predictive model is an efficient, non-invasive, and cost-effective method to predict TIL levels in patients with breast cancer and could facilitate the development of non-invasive biomarkers in precision medicine, as well as the development of a treatment plan.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the Institutional Ethics Review Committee of the China–Japan Friendship Hospital. The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

The acquisition, analysis, data explanation, and manuscript draft were finished by HY. XM is responsible for the analysis and explanation of the radiomics imaging features data. HC analyzed and explained the pathological analysis. JL, WG, LD, YC, YW, XL, and BL acquired the clinical information and revised the manuscript. JF and GM designed the study and made multiple revisions to the manuscript. All authors contributed to the article and approved the submitted version.

**REFERENCES**

1. Emens LAB. Cancer immunotherapy: facts and hopes. *Clin Cancer Res* (2018) 24(3):511–20. doi: 10.1158/1078-0432.CCR-16-3001
2. Santa-Maria CA, Nanda R. Immune checkpoint inhibitor therapy in breast cancer. *J Natl Compr Canc Netw* (2018) 16(10):1259–68. doi: 10.6004/jnccn.2018.7046
3. Hu ZI, Ho AY, McArthur HL. Combined radiation therapy and immune checkpoint blockade therapy for breast cancer. *Int J Radiat Oncol Biol Phys* (2017) 99(1):153–64. doi: 10.1016/j.ijrobp.2017.05.029
4. Fridman WH, Zitvogel L, Sautès-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. *Nat Rev Clin Oncol* (2017) 14(12):717–34. doi: 10.1038/nrclinonc.2017.101
5. Lee HJ, Seo J-Y, Ahn J-H, Ahn S-H, Gong G. Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients. *J Breast Cancer* (2013) 16(1):32–9. doi: 10.4048/jbc.2013.16.1.32
6. Mohammed ZMA, Gomaa JJ, Edwards J, Elsberger B, McMillan DC. The relationship between lymphocyte subsets and clinicopathological determinants of survival in patients with primary operable invasive ductal breast cancer. *Br J Cancer* (2013) 109(6):1676–84. doi: 10.1038/bjc.2013.493
7. Seo AN, Lee HJ, Kim EI, Kim HJ, Jang MH, Lee HE, et al. Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. *Br J Cancer* (2013) 109(10):2705–13. doi: 10.1038/bjc.2013.634
8. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschens F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. *Ann Oncol* (2015) 26(2):259–71. doi: 10.1093/annonc/mdu450
9. Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. *Radiology* (2016) 278(2):563–77. doi: 10.1148/radiol.2015151169
10. Limkin EJ, Sun R, Dercele L, Zacharakis EI, Robert C, Reuzé S, et al. Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology. *Ann Oncol* (2017) 28(6):1191–206. doi: 10.1093/annonc/mdx034
11. Dong D, Zhang F, Zhong L-Z, Fang M-J, Huang C-L, Yao J-J, et al. Development and validation of a novel MR imaging predictor of response to induction chemotherapy in locoregionally advanced nasopharyngeal cancer: a randomized controlled trial substudy (NCT01245959). *BMC Med* (2019) 17(1):190. doi: 10.1186/s12916-019-1422-6
12. Braman NM, Etessami M, Prasanna P, Dubchak C, Gilmore H, Tiwari P, et al. Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI. *Breast Cancer Res* (2017) 19(1):57. doi: 10.1186/s13058-017-0846-1
13. Dong D, Tang L, Li ZY, Fang MJ, Gao JB, Shan XH, et al. Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer. *Ann Oncol* (2019) 30 (3):431–4. doi: 10.1093/annonc/mdz001

14. Bickelhaupt S, Pach D, Kickingereeder P, Steudle F, Lederer W, Daniel H, et al. Prediction of malignancy by a radionomic signature from contrast agent-free diffusion MRI in suspicious breast lesions found on screening mammography. *J Magn Reson Imaging* (2017) 46(2):604–16. doi: 10.1002/jmri.25606

15. Li H, Zhu Y, Burnside ES, Drukker K, Hoadley KA, Fan C, et al. MR imaging radiomics signatures for predicting the risk of breast cancer recurrence as given by research versions of mammprint, oncotypex DX, and PAM50 gene assays. *Radiology* (2019) 281(1):382–91. doi: 10.1148/radiol.2016152110

16. Celebi F, Agacayak F, Ortark A, Ilgan S, Ucunca M, Iygun ZE, et al. Usefulness of imaging findings in predicting tumor-infiltrating lymphocytes in patients with breast cancer. *Eur Radiol* (2020) 30(4):2049–57. doi: 10.1007/s00330-019-06516-x

17. Xie T, Wang Z, Zhao Q, Bai Q, Zhou X, Gu Y, et al. Machine learning-based analysis of MR multiparametric radiomics for the subtype classification of breast cancer. *Front Oncol* (2019) 9:505. doi: 10.3389/fonc.2019.00505

18. Yu H, Meng X, Chen H, Han X, Fan J, Gao W, et al. Correlation between mammographic radiomics Features and the level of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer. *Front Oncol* (2020) 10:412. doi: 10.3389/fonc.2020.00412

19. Ma W, Zhao Y, Ji Y, Guo X, Jian X, Liu P, et al. Breast cancer molecular subtype prediction by mammographic radiomic features. *Acad Radiol* (2019) 26(2):196–201. doi: 10.1016/j.acra.2018.01.023

20. Pruneri G, Vingiani A, Denkert C. Tumor infiltrating lymphocytes in early breast cancer. *Breast* (2018) 37:207–14. doi: 10.1016/j.breast.2017.03.010

21. Denkert C, Loibl S, Budcizjes J, Wiemert S, Klauschen F. [Standardized determination of tumor-infiltrating lymphocytes in breast cancer: A prognostic marker for histological diagnosis]. *Pathologe* (2018) 39 (6):520–31. doi: 10.1007/s00292-018-0530-y

22. Vihervuori H, Autere TA, Repo H, Kuhl S, Kaillo I, Lintunen MM, et al. Tumor-infiltrating lymphocytes and CD8+ T cells predict survival of triple-negative breast cancer. *J Cancer Res Clin Oncol* (2019) 145(12):3105–14. doi: 10.1007/s00432-019-03036-5

23. Wu J, Li X, Teng X, Rubin DL, Napel S, Daniel H, et al. Magnetic resonance imaging and molecular features associated with tumor-infiltrating lymphocytes in breast cancer. *Breast Cancer Res* (2018) 20(1):101. doi: 10.1186/s13058-018-1039-2

24. Fogante M, Tagliati C, De Lisa M, Berardi R, Giuseppetti GM, Giovagnoni A. Correlation between apparent diffusion coefficient of magnetic resonance imaging and tumor-infiltrating lymphocytes in breast cancer. *Radiol Med* (2019) 124(7):581–7. doi: 10.1007/s11547-019-01008-w

25. Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BL, Weber KE, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. *Lancet Oncol* (2018) 19(1):40–50. doi: 10.1016/S1470-2045(17)30904-X

26. Shamir L, Wolkow CA, Goldberg IG. Quantitative measurement of aging using image texture entropy. *Bioinformatics* (2009) 25(23):3060–3. doi: 10.1093/bioinformatics/btp571

27. Pantic I, Pantic S, Paunovic J, Perovic M. Nuclear entropy, angular second moment, variance and texture correlation of thymus cortical and medullar lymphocytes: grey level co-occurrence matrix analysis. *Acad Bras Cienc* (2013) 85(3):1063–72. doi: 10.1590/S0001-37652013005000045

28. Dunnill M, Yip CSF, Ljungqvist G, Selmi M, Ng F, Sanghera B, et al. Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice? *Insights Imaging* (2012) 3(6):573–89. doi: 10.1007/s13244-012-0196-6

29. Kim J-H, Ko ES, Lim Y, Lee KS, Han B-K, Ko EY, et al. Breast cancer heterogeneity: MR imaging texture analysis and survival outcomes. *Radiology* (2017) 282(3):665–75. doi: 10.1148/radiol.2016160261

30. Parikh J, Selmi M, Charles-Edwards G, Glendenning J, Ganeshan B, Verma H, et al. Changes in primary breast cancer heterogeneity may augment midtreatment MR imaging assessment of response to neoadjuvant chemotherapy. *Radiology* (2014) 272(1):100–12. doi: 10.1148/radiol.14130569

31. Park H, Lim Y, Ko ES, Cho H-H, Lee JE, Han B-K, et al. Radiomics signature on magnetic resonance imaging: association with disease-free survival in patients with invasive breast cancer. *Clin Cancer Res* (2018) 24(19):4705–14. doi: 10.1158/1078-0432.CCR-17-3783

32. Lu C-F, Hsu F-T, Hsieh KL-C, Kao Y-CJ, Cheng S-J, Hsu JB-K, et al. Machine learning-based radiomics for molecular subtyping of gliomas. *Clin Cancer Res* (2018) 24(18):4429–36. doi: 10.1158/1078-0432.CCR-17-3445

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Yu, Meng, Chen, Liu, Gao, Du, Chen, Wang, Liu, Liu, Fan and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.